优化非典型症状胃食管反流的评估:成本效果与成本最小化分析
研究建立决策分析模型,比较经验性质子泵抑制剂联合内镜的常规诊疗与一次性全面诊断(含内镜和动态反流监测)在喉咽症状、嗳气或慢性咳嗽患者中的成本效果。结果显示,对喉咽症状和嗳气患者, upfront 全面检测可节省费用并轻微改善QALY;对以咳嗽为主的喉咽症状患者,保险方视角下全面检测具成本效果,但患者视角不一定,决策可留给患者和医生。
要点
- 喉咽症状患者 upfront 检测可识别可安全停用PPI者,节省费用并改善QALY。
- 嗳气患者 upfront 检测可识别胃上嗳气并从膈式呼吸获益,节省费用并改善QALY。
- 咳嗽为主喉咽症状患者全面检测的成本效果因视角而异,决策可个体化。
核心结论
- 按主导症状表型化评估非典型GERD症状患者可能优化诊疗路径。
- 结论与Lyon 2.0和San Diego共识推荐的非GERD管理治疗途径一致。
研究设计与样本
- 决策分析模型,比较经验性PPI联合内镜的常规诊疗与一次性全面诊断(含内镜和动态反流监测)。
- 模型应用于喉咽症状、嗳气和慢性咳嗽患者,从患者和保险方视角分析。
- 时间跨度1年,支付意愿阈值为每获得1个质量调整生命年10万美元。
主要发现
- 喉咽症状患者:upfront检测(含pH/阻抗监测和无线pH监测)可识别可确信停用PPI者,为患者节省220-301美元,为保险方节省约3300美元,每年增加0.01 QALY。
- 嗳气患者:upfront检测(含pH/阻抗监测)可识别从膈式呼吸获益的胃上嗳气患者,为患者节省3424美元,为保险方节省5847美元,每年增加0.10 QALY。
- 咳嗽为主喉咽症状患者:全面检测证实无GERD从保险方视角具成本效果,但从患者视角不一定,决策可留给患者和医生。
关键数值与推荐
- 支付意愿阈值为每获得1个QALY 10万美元。
- 喉咽症状患者upfront检测节省:患者220-301美元,保险方约3300美元,+0.01 QALY/年。
- 嗳气患者upfront检测节省:患者3424美元,保险方5847美元,+0.10 QALY/年。
临床怎么用
- 对喉咽症状和嗳气患者可考虑 upfront 全面诊断(含内镜和动态反流监测)以指导治疗。
- 对咳嗽为主喉咽症状患者,是否全面检测应结合支付方视角和患者偏好个体化决策。
- 识别胃上嗳气患者可指导膈式呼吸治疗,避免不必要的GERD管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many patients with laryngopharyngeal symptoms (LPS), chronic cough, or belching are referred to gastroenterologists for evaluation and management of gastroesophageal reflux disease (GERD). We aimed to optimize a cost-effective approach to evaluating atypical GERD symptoms. METHODS: We developed a decision analytic model comparing common strategies: (1) usual care defined by empiric proton pump inhibitors and endoscopy, or (2) comprehensive 1-time diagnostics including endoscopy and ambulatory reflux testing to guide therapy. The model was applied to patients with LPS, belching, and chronic cough from patient and insurer perspectives. The time horizon was 1 year, and the willingness-to-pay threshold was set to $100,000/quality-adjusted life-year (QALY) gained. RESULTS: For patients with LPS, upfront testing, including pH/impedance monitoring and wireless pH monitoring, optimized cost-effectiveness by identifying patients who can convincingly stop proton pump inhibitor therapy ($220-$301 saved to patients, ∼$3300 saved to insurers, +0.01 QALY gained/year). For patients with belching, upfront testing, including pH/impedance monitoring, optimized cost-effectiveness by identifying patients with supragastric belching who would benefit from diaphragmatic breathing ($3424 saved to patients, $5847 saved to insurers, +0.10 QALY gained/year). For patients with cough-predominant LPS, demonstration that GERD is absent with comprehensive testing appears cost-effective from an insurers' perspective, but not necessarily from patients' perspective, and the decision can be left to the patients and providers. CONCLUSIONS: Phenotyping the approach to the dominant symptom may optimize evaluating patients with atypical GERD symptoms. These conclusions are consistent with the Lyon 2.0 and San Diego consensus recommendations of treatment avenues distinct from GERD management.
引用
- Shah ED, Yadlapati R, Chan WW, et al. Optimizing Evaluation of Gastroesophageal Reflux With Atypical Symptoms: Cost-Effectiveness and Cost-Minimalization Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 41297738. doi:10.1016/j.cgh.2025.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。